Brentuximab VedotinCHANGCHUN DENG; BEIQING PAN; O'CONNOR, Owen A et al.Clinical cancer research (Print). 2013, Vol 19, Num 1, pp 22-27, issn 1078-0432, 6 p.Article

Pagetoid reticulosis with CD30 positivity and cytotoxic/suppressor cellsJACYK, Witold K; GRAYSON, Wayne; DINKEL, Jurgen Erich et al.Journal of cutaneous pathology. 2007, Vol 34, Num 8, pp 644-647, issn 0303-6987, 4 p.Article

Lymphome à grandes cellules Ki1 avec xanthomisation des lésions sous chimiothérapie = Large cell Ki1 lymphoma with chemotherapy induced xanthomisationMOULONGUET, I; PERRIN, P; ISKANDAR, M. J et al.Annales de dermatologie et de vénéréologie. 1989, Vol 116, Num 11, pp 887-889, issn 0151-9638, 3 p.Conference Paper

Assignment of the human CD30 (Ki-1) gene to 1p36FONATSCH, C; LATZA, U; DÜRKOP, H et al.Genomics (San Diego, Calif.). 1992, Vol 14, Num 3, pp 825-826, issn 0888-7543Article

Lymphomes à grandes cellules anaplasiques CD30 (Ki-1)⁺ = CD30(Ki1)+anaplasic large cell lymphomasBAGOT, M; WECHSLER, J; COSNES, A et al.Annales de dermatologie et de vénéréologie. 1989, Vol 116, Num 11, pp 881-883, issn 0151-9638, 3 p.Conference Paper

Large CD30-positive cells in benign, atypical lymphoid infiltrates of the skinWERNER, Betina; MASSONE, Cesare; KERL, Helmut et al.Journal of cutaneous pathology. 2008, Vol 35, Num 12, pp 1100-1107, issn 0303-6987, 8 p.Article

CD27/CD70, CD134/CD134 ligand, and CD30/CD153 pathways are independently essential for generation of regulatory cells after intratracheal delivery of alloantigenARAMAKI, Osamu; SHIRASUGI, Nozomu; NIIMI, Masanori et al.Transplantation. 2003, Vol 76, Num 5, pp 772-776, issn 0041-1337, 5 p.Article

Signet-ring cell lymphoma of T-cell type with CD30 expressionBELLAS, C; MOLINA, A; MONTALBAN, C et al.Histopathology. 1993, Vol 22, Num 2, pp 188-189, issn 0309-0167Article

Circulating Soluble CD27 and CD30 in Workers Exposed to 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD)FATEMEH SABERI HOSNIJEH; PORTENGEN, Lützen; BUENO-DE-MESQUITA, H. Bas et al.Cancer epidemiology, biomarkers & prevention. 2013, Vol 22, Num 12, pp 2420-2424, issn 1055-9965, 5 p.Article

Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug ConjugateOKELEY, Nicole M; MIYAMOTO, Jamie B; XINQUN ZHANG et al.Clinical cancer research (Print). 2010, Vol 16, Num 3, pp 888-897, issn 1078-0432, 10 p.Article

Decreasing soluble CD30 and increasing IFN-γ plasma levels are indicators of effective highly active antiretroviral therapySADEGHI, Mahmoud; SÜSAL, Caner; DANIEL, Volker et al.AIDS research and human retroviruses. 2007, Vol 23, Num 7, pp 886-890, issn 0889-2229, 5 p.Article

High expression of the CD30 molecule in human decidual cellsITO, K; WATANABE, T; HORIE, R et al.The American journal of pathology. 1994, Vol 145, Num 2, pp 276-280, issn 0002-9440Article

Expression and a role of CD30 in regulation of T-cell activityTARKOWSKI, Maciej.Current opinion in hematology. 2003, Vol 10, Num 4, pp 267-271, issn 1065-6251, 5 p.Article

ADAM10 inhibition of human CD30 shedding increases specificity of targeted immunotherapy in vitroEICHENAUER, Dennis A; SIMHADRI, Vijaya Lakshmi; HANSEN, Hinrich P et al.Cancer research (Baltimore). 2007, Vol 67, Num 1, pp 332-338, issn 0008-5472, 7 p.Article

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive LymphomasYOUNES, Anas; BARTLETT, Nancy L; LEONARD, John P et al.The New England journal of medicine. 2010, Vol 363, Num 19, pp 1812-1821, issn 0028-4793, 10 p.Article

A Distinct Entity in the Spectrum of the CD30+ Cutaneous Lymphoproliferative Diseases : Oligolesional Nodules With Pseudoepitheliomatous Hyperplasia Followed by Spontaneous ResolutionZAYOUR, Maya; GILMORE, Elaine; HEALD, Peter et al.The American journal of dermatopathology. 2009, Vol 31, Num 1, pp 37-43, issn 0193-1091, 7 p.Article

Atteinte muqueuse dans la papulose lymphomatoïde : quatre cas = Mucosal involvement in lymphomatoid papulosis : Four casesALLABERT, C; ESTEVE, E; JOLY, P et al.Annales de dermatologie et de vénéréologie. 2008, Vol 135, Num 4, pp 273-278, issn 0151-9638, 6 p.Article

In vivo drug-linker stability of an anti-cd30 dipeptide-linked auristatin immunoconjugateSANDERSON, Russell J; HERING, Michelle A; JAMES, Stephanie F et al.Clinical cancer research. 2005, Vol 11, Num 2, pp 843-852, issn 1078-0432, 10 p., 1Article

Serum levels of soluble CD26 and CD30 in patients on hemodialysisNAKAO, Kazushi; NAGAKE, Yoshio; OKAMOTO, Akira et al.Nephron. 2002, Vol 91, Num 2, pp 215-221, issn 0028-2766Article

CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO⁺ T cellsELLIS, T. M; SIMMS, P. E; SLIVNICK, D. J et al.The Journal of immunology (1950). 1993, Vol 151, Num 5, pp 2380-2389, issn 0022-1767Article

Clusterin expression in cutaneous CD30-positive lymphoproliferative disorders and their histologic simulantsOLSEN, Stephen H; LINGLEI MA; SCHNITZER, Bertram et al.Journal of cutaneous pathology. 2009, Vol 36, Num 3, pp 302-307, issn 0303-6987, 6 p.Article

Soluble CD30 as a prognostic factor for outcome following renal transplantationPLATT, R. E; WU, K. S. T; POOLE, K et al.Journal of clinical pathology. 2009, Vol 62, Num 7, pp 662-663, issn 0021-9746, 2 p.Article

Roles for CD30 in the biology and treatment of CD30⁺ lymphoproliferative diseasesGRANADOS, Suzanne; HWANG, Sam T.Journal of investigative dermatology. 2004, Vol 122, Num 6, pp 1345-1347, issn 0022-202X, 3 p.Article

Biology of human T_H1 and T_H2 cellsROMAGNANI, S.Journal of clinical immunology. 1995, Vol 15, Num 3, pp 121-129, issn 0271-9142Article

Primary cutaneous pleomorphic T-cell lymphoma expressing CD30 antigenGIANOTTI, R; ALESSI, E; CAVICCHINI, S et al.The American journal of dermatopathology. 1991, Vol 13, Num 5, pp 503-508, issn 0193-1091Article